What is Circassia?
Founded in 2006 and headquartered in Oxford, UK, Circassia operates at the intersection of medical technology and respiratory care. The company is primarily dedicated to the development of advanced diagnostic tools and management systems designed to improve patient outcomes for those suffering from asthma. By leveraging deep scientific research and clinical expertise, Circassia has established itself as a pivotal player in the life sciences industry, focusing on high-precision diagnostics that address significant unmet needs in chronic respiratory disease management.
The company's market position is bolstered by a history of sustained financial backing from institutional investors who recognize the long-term value of its diagnostic pipeline. Through its evolution, Circassia has transitioned from early-stage development to a mature enterprise capable of executing complex market strategies and large-scale clinical initiatives.
How much funding has Circassia raised?
Circassia has raised a total of $667.3M across 7 funding rounds:
Series A
$7.5M
Series B
$21.8M
Series C
$25M
Series D
$98M
Other Financing Round
$154M
Series E
$19M
Stock Offering
$342M
Series A (2007): $7.5M with participation from Undisclosed
Series B (2008): $21.8M led by Lansdowne Partners, Invesco, Imperial Innovations, and Goldman Sachs
Series C (2009): $25M supported by Lansdowne Partners, Imperial Innovations, and Invesco
Series D (2011): $98M featuring Invesco and Imperial Innovations
Other Financing Round (2012): $154M backed by Invesco and Imperial Innovations
Series E (2012): $19M with participation from Imperial Innovations and Invesco
Stock Issuance/Offering (2015): $342M led by Undisclosed
Key Investors in Circassia
Invesco
Invesco is a global, publicly owned investment manager providing comprehensive financial services to institutional and retail clients, with a focus on diverse asset classes including equity and fixed income.
Imperial Innovations
Imperial Innovations serves as the commercialization arm for Imperial College London, focusing on translating world-class scientific research into viable, high-growth industrial technologies.
Lansdowne Partners
Lansdowne Partners is a London-based investment management firm dedicated to delivering superior long-term returns through disciplined, research-driven investment strategies.
What's next for Circassia?
Looking ahead, the infusion of capital from its most recent financing round positions Circassia to accelerate its commercialization efforts and deepen its research capabilities. The company is expected to prioritize the integration of its diagnostic platforms into broader clinical workflows, potentially enhancing its competitive advantage in the asthma management space. As the firm continues to mature, strategic focus will likely shift toward international market penetration and the potential expansion of its diagnostic portfolio to address related respiratory conditions, ensuring sustained growth and long-term value creation for its stakeholders.
See full Circassia company page
